|
| CASE REPORT |
|
|
|
| Year : 2009 | Volume
: 41
| Issue : 4 | Page : 203-204 |
| |
Docetaxel-induced photolichenoid eruption
Biju Vasudevan1, M.P.S. Sawhney1, Nitu Sharma2
1 Department of Dermatology, Base Hospital, Delhi Cantt, New Delhi, India
2 Department of Pathology, Base Hospital, Delhi Cantt, New Delhi, India
| Date of Submission | 29-Dec-2008 |
| Date of Decision | 31-Jan-2009 |
| Date of Acceptance | 01-Jul-2009 |
| Date of Web Publication | 26-Sep-2009 |
Correspondence Address:
Biju Vasudevan
Department of Dermatology, Base Hospital, Delhi Cantt, New Delhi
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.56065
A 58-year-old man presented with complaints of blackish discoloration of forearms and face of five months duration. The lesions occurred episodically after taking anti-cancer medications, each episode lasting for two weeks. Histopathology confirmed a lichenoid eruption. Photolichenoid eruption to docetaxel is a dermatological adverse effect not reported in literature earlier.
Keywords: Adverse effects, docetaxel, lichenoid eruption
How to cite this article:
Vasudevan B, Sawhney M, Sharma N. Docetaxel-induced photolichenoid eruption. Indian J Pharmacol 2009;41:203-4 |
| » Introduction | |  |
Docetaxel is a clinically well established antineoplastic medication used mainly for the treatment of breast, ovarian, prostate and non-small cell lung cancer. [1] Docetaxel acts by stabilizing microtubules, enhancing the rate and extent of tubulin polymerization and inhibiting depolymerization. The main toxic effects of the drug are neutropenia, fluid retention, asthenia, neurotoxicity, hypersensitivity and cutaneous reactions. [2] We herein describe a case of photolichenoid eruption as a side effect of docetaxel, which has not been reported in literature earlier.
| » Case Report | | |
A 58-year-old male on treatment for prostate cancer since two years, presented to the skin OPD with complaints of dark colored raised lesions on hands and face of three days duration. He initially noticed lesions on the face which spread to involve the neck and both forearms and hands. The lesions were associated with moderate to severe itching which increased on sun exposure. There was history of such episodic appearance of lesions for the last four to five months. He was taking docetaxel injections for prostate cancer once in three weeks since five months. The lesions had initially appeared two to three days after the first injection, according to his case history. Subsequently they would fade in two weeks but again flare up after the next injection. The patient was not administered any other drug simultaneously for the same disease or for any other associated or non associated disease condition.
On examination, violaceous, well defined, non scaly, non tender plaques were present on the dorsum of hands, extensor surface of forearms, face and front of neck [Figure 1] and [Figure 2]. Only the photo exposed parts of the face were involved. Systemic examination was within normal limits. A clinical diagnosis of drug induced photolichenoid eruption with differential diagnosis of discoid lupus erythematosus was kept in mind. On investigating, the patient had microcytic hypochromic anemia with hemoglobin of 9.8gm%. The differential white blood cell (WBC) count showed increased eosinophils with an absolute eosinophilic count of 850/ mm 3 . All other hematological and biochemical parameters were within normal limits. ANA and dsDNA were repeatedly negative. Skin biopsy revealed a band like lymphocytic infiltrate along the dermo epidermal junction along with abundant melanophages and a mixed eosinophilic-lymphocyte infiltrate in dermis [Figure 3]. A diagnosis of photolichenoid eruption to docetaxel was thus confirmed. The medication was stopped and replaced by estramustine phosphate. Sunscreen, topical corticosteroid cream and tab Avil were prescribed. The lesions regressed in one week. The patient has been observed for six months following change of therapy. No fresh lesions have been observed.
| » Discussion | | |
Docetaxel is of the chemotherapy drug class taxane and is a semi-synthetic analogue of Paclitaxel, an extract from the rare Pacific yew tree Taxus brevifolia. It has the empiric formula C 43 H 53 NO 14 .3H 2 O with a molecular weight of 861.9. Docetaxel differs from paclitaxel at two positions in its chemical structure. It has a hydroxyl functional group on carbon 10, whereas paclitaxel has an acetate ester and a tertiary-butyl substitution exists on the phenyl propionate side chain. The carbon 10 functional group change causes docetaxel to be more lipid soluble than paclitaxel. Intravenous administration of docetaxel results in 100% bioavailability and absorption is immediate. Administered as a one-hour infusion every three weeks, generally over a 20 cycle course, it has a half life of 11-18 hrs and is metabolized in the liver by cytochrome P450-3A. [3],[4] About 80% of elimination is through the feces while five per cent is excreted in urine; 95% of the drug is bound to plasma proteins.
As docetaxel is a cell cycle specific agent it is cytotoxic to all dividing cells in the body [5] and hence exhibits cytotoxic activity on breast, colorectal, lung, ovarian, gastric, renal and prostate cancer cells. Docetaxel has also been found to have greater cellular uptake and is retained longer intracellularly than paclitaxel allowing docetaxel treatment to be effective with a smaller dose, leading to fewer and less severe adverse effects. Docetaxel is contraindicated for use with patients with; baseline neutrophil count less than 1.5 x 109 cells/L, history of severe hypersensitivity reactions to docetaxel or polysorbate, severe liver impairment and pregnant or breast-feeding women. Erythromycin, ketoconazole and cyclosporine are CYP3A4 inhibitors and therefore inhibit the metabolic pathway of docetaxel. When used with anticonvulsants which induce CYP3A4 an increased dose of docetaxel may be required. Elderly people are especially sensitive to the effects of docetaxel. This may increase the chance of side effects during treatment.
Major systemic side effects of docetaxel include bone marrow suppression, hypersensitivity reactions, fluid retention, neurotoxicity, myositis and cardiovascular side effects. Hematological adverse effects include neutropenia, anemia, febrile neutropenia and thrombocytopenia. Hypersensitivity reactions can range from minor rash to severe anaphylaxis. Fluid retention can take the form of generalized edema, pleural effusion and ascites, all of which are reversible on stopping treatment. Other rare effects include vomiting, diarrhea, asthenia and arthralgias. Premedication with Oral corticosteroids is advised starting from a day before infusion and lasting for four to five days to prevent these adverse effects.
Skin reactions mentioned in literature include maculopapular drug rash, supravenous discoloration, mucosal ulcers, alopecia, nail hyper pigmentation and destruction. [6] Docetaxel may also produce a potentially life-threatening, toxic epidermal necrolysis-like adverse reaction. In our case the patient had photolichenoid eruption following the cyclic administration of docetaxel. This was confirmed clinically and by the classic histopathology. Such a dermatological adverse effect of the drug has not been mentioned in literature earlier. As docetaxel is now a widely used antineoplastic drug, clinicians should take into consideration the above-described side effect while prescribing it.
| » References | | |
| 1. | Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999;36:99-114.  |
| 2. | Chiappori A, Devore RF, Johnson DH. New agents in the management of non-small lung cancer. Cancer Control 1997;4:317-25. |
| 3. | Lyseng-Williamson KA, Fenton C. Docetaxel: A review of its use in metastatic breast cancer. Drugs 2005;65:2513-31. |
| 4. | Guitton J, Cohen S, Tranchand B, Vignal B, Droz JP, Guillaumont M, et al. Quantification of docetaxel and its main metabolites in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2005;9:2419-26. |
| 5. | Eisenhauer EA, Vermorken JB. The taxoids: Comparative clinical pharmacology and therapeutic potential. Drugs 1998;55:5-30. |
| 6. | Aydogan I, Kavak A, Parlak, Alper M, Annakkaya AN, Erbas M. Persistent serpentine supravenous hyperpigmented eruption associated with docetaxel. J Eur Acad Dermatol Venereol 2005;19:345. |
[Figure 1], [Figure 2], [Figure 3]
| This article has been cited by | | 1 |
A Rare Case of Life-Threatening Extensive Mucocutaneous Adverse Reaction Induced by Docetaxel in a Breast Cancer Patient: Toxic Epidermal Necrolysis, a Case Report with Review of Literature |
|
| Shiv Prasad Shrivastava, Aditya Elhence, Prutha Jinwala, Shashank Bansal, Prakash Chitalkar, Shweta Bhatnagar, Rajesh Patidar, Vikas Asati | | Indian Journal of Medical and Paediatric Oncology. 2022; | | [Pubmed] | [DOI] | | | 2 |
Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-negative metastatic breast cancer |
|
| Hazem Ghebeh, Adher Al-Sayed, Riham Eiada, Leilani Cabangon, Dahish Ajarim, Kausar Suleman, Asma Tulbah, Taher Al-Tweigeri | | Scientific Reports. 2021; 11(1) | | [Pubmed] | [DOI] | | | 3 |
Dermatologic adverse effects of breast cancer chemotherapy: a longitudinal prospective observational study with a review of literature |
|
| Narges Alizadeh, Seyyed Hossein Mirpour, Abbas Darjani, Rana Rafiei, Elahe Rafiei, Maryam Mohammadhoseini | | International Journal of Dermatology. 2020; 59(7): 822 | | [Pubmed] | [DOI] | | | 4 |
Cytostatic and cytotoxic drugs |
|
| Gupta, A., Middleton, M. | | Side Effects of Drugs Annual. 2011; 33(1): 935-962 | | [Pubmed] | | | 5 |
Screening of some plant extracts against some skin diseases caused by oxidative stress and microorganisms |
|
| Chanda, S., Baravalia, Y. | | African Journal of Biotechnology. 2010; 9(21): 3210-3217 | | [Pubmed] | |
|
|
|
|
|
|
|
|
